Company Overview and News

1
PIRS / Pieris Pharmaceuticals, Inc. S-8

2018-08-09 sec.gov
Document As filed with the Securities and Exchange Commission on August 9, 2018 Registration No. 333-____ <
PIRS

1
PIRS / Pieris Pharmaceuticals, Inc. S-8

2018-08-09 sec.gov
Document As filed with the Securities and Exchange Commission on August 9, 2018 Registration No. 333-____
PIRS

1
PIRS / Pieris Pharmaceuticals, Inc. S-3

2018-08-09 sec.gov
Document As filed with the Securities and Exchange Commission on August 9, 2018 No. 333- _______
PIRS

1
Pieris Pharmaceuticals. Inc (PIRS) CEO Stephen Yoder on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Greetings and welcome to the Pieris Pharmaceuticals 2018 Second Quarter Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
SGEN PIRS

5
Pieris Pharmaceuticals (PIRS) Reports Break-Even Earnings for Q2

2018-08-09 zacks - 2
Pieris Pharmaceuticals (PIRS - Free Report) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.01. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.
PIRS HCCDZ HCHC GWRS UCTI SND RLH UCTT

1
PIRS / Pieris Pharmaceuticals, Inc. 8-K (Current Report)

2018-08-09 sec.gov
Document UNITED STATES
PIRS

1
PIRS / Pieris Pharmaceuticals, Inc. null

2018-08-06 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A
PIRS

1
Pieris Pharmaceuticals to Host Second Quarter 2018 Investor Call and Corporate Update on August 9, 2018

2018-08-01 globenewswire
BOSTON, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it will host a second quarter 2018 investor call on Thursday, August 9, 2018 at 8:00 AM (EDT) to discuss financial results and provide a corporate update.
PIRS

1
PIRS / Pieris Pharmaceuticals, Inc. 10-Q/A (Quarterly Report)

2018-07-31 sec.gov
Document UNITED STATES
PIRS

1
PIRS / Pieris Pharmaceuticals, Inc. 8-K (Current Report)

2018-07-27 sec.gov
Document UNITED STATES
PIRS

1
PIRS / Pieris Pharmaceuticals, Inc. / Biotechnology Value Fund L P - AMENDMENT NO. 3 TO THE SCHEDULE 13G (Passive Investment)

2018-07-12 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (R
PIRS

1
PIRS / Pieris Pharmaceuticals, Inc. / Biotechnology Value Fund L P - AMENDMENT NO. 3 TO THE SCHEDULE 13G (Passive Investment)

2018-07-12 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (R
PIRS

46
PIRS / Pieris Pharmaceuticals, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 7 (Activist Investment)

2018-06-22 sec.gov - 5
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PIRS

45
PIRS / Pieris Pharmaceuticals, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 7 (Activist Investment)

2018-06-22 sec.gov - 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PIRS

PIRS : Pieris Pharmaceuticals Stock Analysis and Research Report

2017-10-20 - Asif

Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Pieris' pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. Each of its development programs focus on the following: 300-Series oncology drug candidates are multispecific Anticalin®-based proteins designed to engage immunomodulatory targets and consist of a variety of multifunctional biotherapeutics that genetically link antibody with one or more Anticalin proteins, thereby constituting...

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 720795103